JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a ...

Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...

JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Longer Term Trading Plans for ATXS. Buy ATXS near 7.19 target 9.02 stop loss @ 7.17 Details; The technical summary data tells us to buy ATXS near 7.19 with an upside target of 9.0 ...

LifeSprout, a privately held regenerative medicine company founded with technology licensed from Johns Hopkins University, today announced it has filed for CE Mark registration for ...

BCT EXP, a global leader in digital transformation, user experiences, cross platform technologies and enterprise systems, today announced a formal partnership with OutSystems, a recognized pioneer in ...

According to a recent press release from Astria Therapeutics, the trial is anticipated to be initiated in the first quarter of 2025. Top-line results from ALPHA-ORBIT are expected in early 2027. The ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...